The A3 trial -- Antibody Drug Conjugate (ADC) After ADC -- which addressed a similar question found a median PFS of 3.24 months for the second ADC, even with a change in antibody target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback